- Home
- CGAU vs DYN Comparison
CGAU vs DYN Comparison
Compare CGAU & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGAU
- DYN
- Stock Information
- Founded
- CGAU 2002
- DYN 1984
- Country
- CGAU Canada
- DYN United States
- Employees
- CGAU N/A
- DYN N/A
- Industry
- CGAU Precious Metals
- DYN Medicinal Chemicals and Botanical Products
- Sector
- CGAU Basic Materials
- DYN Health Care
- Exchange
- CGAU Nasdaq
- DYN Nasdaq
- Market Cap
- CGAU 1.5B
- DYN 1.4B
- IPO Year
- CGAU N/A
- DYN 2020
- Fundamental
- Price
- CGAU $7.16
- DYN $8.98
- Analyst Decision
- CGAU Buy
- DYN Strong Buy
- Analyst Count
- CGAU 2
- DYN 15
- Target Price
- CGAU $12.00
- DYN $43.60
- AVG Volume (30 Days)
- CGAU 916.5K
- DYN 3.4M
- Earning Date
- CGAU 08-06-2025
- DYN 08-11-2025
- Dividend Yield
- CGAU 2.84%
- DYN N/A
- EPS Growth
- CGAU N/A
- DYN N/A
- EPS
- CGAU 0.18
- DYN N/A
- Revenue
- CGAU $1,208,123,000.00
- DYN N/A
- Revenue This Year
- CGAU N/A
- DYN N/A
- Revenue Next Year
- CGAU $8.11
- DYN N/A
- P/E Ratio
- CGAU $38.35
- DYN N/A
- Revenue Growth
- CGAU 2.88
- DYN N/A
- 52 Week Low
- CGAU $5.41
- DYN $6.36
- 52 Week High
- CGAU $7.82
- DYN $47.45
- Technical
- Relative Strength Index (RSI)
- CGAU 46.54
- DYN 33.36
- Support Level
- CGAU $6.99
- DYN $8.06
- Resistance Level
- CGAU $7.54
- DYN $10.74
- Average True Range (ATR)
- CGAU 0.21
- DYN 0.58
- MACD
- CGAU -0.02
- DYN -0.26
- Stochastic Oscillator
- CGAU 21.87
- DYN 20.49
About CGAU Centerra Gold Inc.
Centerra Gold Inc a gold mining and exploration company engaged in the operation, exploration, development, and acquisition of gold properties in Asia, North America, and other markets world-wide. The company reportable operating segments are Oksut; Mount; and Milligan Molybdenum. It derives maximum revenue from Oksut segment. Geographically, it operates in Turkey, United States, Canada and Other.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.